Description
An orally bioavailable antagonist of CCR5 and CCR2 (IC50s = 2.3 and 5.9 nM, respectively, for receptors in CHO cells); an antagonist of CCR3 and CCR4 (IC50s = 2.4 and 1.1 μM, respectively); completely inhibits replication of R5 HIV-1 in U87.CD4.CCR5 cells (100 nM); inhibits replication of the R5 HIV-1 strains JR-FL and KK in PBMCs (EC50s = 21-210 pM and 33-91 pM, respectively); reduces collagen deposition, levels of collagen type 1 protein and mRNA expression, and non-alcoholic fatty liver disease activity score in a mouse model of NASH (20 mg/kg per day); reduces collagen type 1 protein levels, mRNA expression, and collagen deposition in a mouse model of unilateral ureter obstruction and a rat model of thioacetamide-induced liver fibrosis
Formal name: 8-[4-(2-butoxyethoxy)phenyl]-1,2,3,4-tetrahydro-1-(2-methylpropyl)-N-[4-[(S)-[(1-propyl-1H-imidazol-5-yl)methyl]sulfinyl]phenyl]-1-benzazocine-5-carboxamide
Synonyms: TAK-652
Molecular weight: 696.9
CAS: 497223-25-3
Purity: ≥95%
Formulation: A crystalline solid
Product Type|Biochemicals|Antivirals|CCR5 Receptor Antagonists||Product Type|Biochemicals|Receptor Pharmacology|Antagonists||Research Area|Endocrinology & Metabolism|Metabolic Diseases|NAFLD & NASH||Research Area|Immunology & Inflammation|Innate Immunity||Research Area|Infectious Disease|Viral Diseases|HIV & AIDS